Novartis/ThromboGenics' jet off with EU go-ahead and US launch for Jetrea
This article was originally published in Scrip
The EU's CHMP has granted a positive opinion for marketing to Novartis/ ThromboGenics' Jetrea (ocriplasmin), the first drug for treating the sight-threatening eye disorder, vitreomacular traction. The go-ahead comes just days after ThromboGenics launched the product in the US on 14 January, its first market, following FDA approval in October (scripintelligence.com, 4 January 2013).
You may also be interested in...
A highly impressive improvement in disease-free survival in ADAURA is set to pitch AstraZeneca’s best-selling product into a new untapped market, early-stage EGFRm NSCLC, reaping a possible $3bn in extra sales.
The largest-ever rise in the number of active R&D companies, particularly in China, helped propel an unprecedented increase in the size of the biopharma pipeline in 2019. Meanwhile, the number of new active substances launched in their first market last year dropped as 2018’s superlative performance gave way to something more usual.
Kadmon’s treatment for graft-versus-host disease, belumosudil continues to perform well in its pivotal ROCKstar study, setting the stage for a US filing under the FDA’s pilot Real-Time Oncology Review program.